Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease

YALÇIN, H. Cahit; Ünsal, Belkıs; PAYZİN, Bahriye; BERKMEN, Sibel; ÇETİNKAYA, Gülbin S.; ERASLAN, Sibel; ADAKAN, Yeşim

Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease

Bahriye PAYZİN, (İzmir Atatürk Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, İzmir, Türkiye)

Yeşim ADAKAN, (İzmir Atatürk Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, İzmir, Türkiye)

H. Cahit YALÇIN, (İzmir Atatürk Eğitim ve Araştırma Hastanesi, Gastroenteroloji Kliniği, İzmir, Türkiye)

Gülbin S. ÇETİNKAYA, (İzmir Atatürk Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, İzmir, Türkiye)

Sibel BERKMEN, (İzmir Atatürk Eğitim ve Araştırma Hastanesi, Gastroenteroloji Kliniği, İzmir, Türkiye)

Sibel ERASLAN, (Düzen Laboratuvarı, İstanbul, Türkiye)

Belkıs ÜNSAL (İzmir Atatürk Eğitim ve Araştırma Hastanesi, Gastroenteroloji Kliniği, İzmir, Türkiye)

Turkish Journal of Gastroenterology

0 0

Yıl: 2006 Cilt: 17 Sayı: 3 Sayfa Aralığı: 183 - 190 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease

Öz:

Amaç: Tromboembolik olaylar inflamatuvar barsak hastalıklarının nadir fakat anlamlı bir komplikasyonudur. Bu çalışmada amaç inflamatuvar barsak hastası olan Türk hastalar-daki doğal koagulasyon inhibitörlerinin seviyesinin ve aktive protein C direncinin araştırılmasıdır. Yöntem: Tromboz öyküsü olmayan 50 hasta (29 erkek, 21 kadın) ve 37 sağlıklı kontrol çalışmaya alındı. Eritrosit sedimentasyon hızı, C reaktif protein, trombosit sayısı, protrombin zamanı, aktive parsiyel prot-ronıbin zamanı, fibrinojen, von Willebrand faktör antijeni, FVI-II aktivitesi, aktive protein C rezistansı, Antitrombin III, protein C and protein S fonksiyonel düzeyleri ölçüldü. Aktive protein C rezistansı olan hasta ve kontrollerde daha sonra polimeraz zincir reaksiyonu kullanılarak faktör V Leiden mutasyonu çalışıldı. Bulgular: Hasta ve kontroller arasında Antitrombin III, protein C, protein S, FVIII ve von Willebrand faktör düzeyleri arasında anlamlı fark yoktu. Remisyondaki hastalar ve kontrollerle kıyaslandığında ortalama trombosit sayısı, fibrinojen düzeyi, von Willebrand faktör düzeyi hastalığın aktif döneminde anlamlı olarak yüksek bulundu. Aktive protein C rezistansı ve faktör V Leiden mutasyonu gösteren hasta yüzdesinde hasta ve kontroller arasında anlamlı bir fark gözlenmedi. Sonuç: Tromboza eğilim gösteren aktive protein C rezistansı ve doğal koagulasyon inhibitörlerin eksikliği gibi kalıtsal bozuklukları aktif dönemdeki ve remisyondaki inflamatuvar barsak hastası olan Türk hastalarda saptamadık. Tromboz öyküsü bulunan hastalarda böyle bir kontrollü çalışma yapılmasını öneririz.

Anahtar Kelime: Kan trombositleri Kan pıhtılaşma faktörleri Kısmi tromboplastin zamanı Kan pıhtılaşma faktör inhibitörleri Remisyon, spontan Polimeraz zincir reaksiyonu Kan sedimentasyonu Faktör V leiden Aktive protein C direnci C-reaktif protein Biyolojik belirteçler Protrombin zamanı Olgu-kontrol çalışmaları Enflamatuvar bağırsak hastalıkları Tromboembolizim Faktör V Nokta mutasyonu

Konular: Cerrahi

Türk inflamatuvar barsak hastalarında doğal koagülasyon inhibitör proteinleri ve active protein C direnci

Öz:

Background/aims: Thromboembolic events are a rare but significant complication of inflammatory bowel disease. The aim of this study was to investigate the level of natural coagulation inhibitors and activated protein C resistance in Turkish patients with inflammatory bowel disease. Methods: Fifty patients (29 male, 21 female) without venous thrombosis history and 37 healthy controls were included in the study. Erythrocyte sedimentation rate, C-reactive protein, thrombocyte count, prothrombin time, activated partial thromboplastin time, fibrinogen concentration, von Willebrand factor antigen, factor VIII activity, activated protein C resistance, functional levels of antithrombin III, protein C and protein S were measured. Patients and controls with activated protein C resistance were further studied using a polymerase chain reaction assay for factor V Leiden mutation. Results: There was no significant difference between patients and the controls in terms of antithrombin III, protein C, protein S, factor (F) VIII and Willebrand factor levels. The mean thrombocyte counts, fibrinogen levels, and Willebrand factor levels were found to be significantly higher in patients who were in the active period of the disease than in controls and patients in remission. No significant difference was observed in those showing activated protein C resistance and factor V Leiden mutation between patients and controls. Conclusions: The presence of inherited thrombophilic defects, in particular activated protein C resistance and natural coagulation inhibitor deficiency, is uncommon in Turkish patients with inflammatory bowel disease in both active and remission periods. As a result, a controlled study in inflammatory bowel disease patients with thrombosis history is recommended.

Anahtar Kelime: Activated Protein C Resistance C-Reactive Protein Biological Markers Prothrombin Time Case-Control Studies Inflammatory Bowel Diseases Thromboembolism Factor V Point Mutation Blood Platelets Blood Coagulation Factors Partial Thromboplastin Time Blood Coagulation Factor Inhibitors Remission, Spontaneous Polymerase Chain Reaction Blood Sedimentation Factor V leiden

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Novacek G, Miehsler W, Kapiotis S. Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94: 685-90.
2. Liebman HA, Kashani N, Sutherland D. The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. Gastroenterology 1998; 115: 830-4.
3. Koutroubakis IE, Sfiridaki A, Mouzas UA. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95: 190-4.
4. Conlan M, Haire WD, Burnett DA. Prothrombotic abnormalities in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1089-93.
5. Koutroubakis IE. Therapy insight: vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Cardiovasc Med. 2005; 2: 266-72.
6. Hudson M, Chitolie A, Hutton RA. Thrombotic vascular risk factors in inflammatory bowel disease. Gut 1996; 38: 733-7.
7. Sankey EA, Dhillon AP, Anthony A, et al. Early mucosal changes in Crohn’s disease. Gut 1993; 34: 375-81.
8. Thompson NP, Wakefield JA, Pounder ER. Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 1995; 108: 1011-15.
9. Koutroubakis IE. Unraveling the mechanisms of thrombosis in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 1325-7.
10. Mahmood A, Needham J, Prosser J, Mainwaring J. Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2005; 17: 739-44.
11. Attvall E, Frigyesi A, Sternby B. What is the impact of resistance to activated protein C (Leiden mutation to factor V) in inflammatory bowel disease? Int J Colorectal Dis 2006; 13: 1-6.
12. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterised by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
13. Koster T, Rosendaal FR, de Ronde H. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
14. Larsen TB, Nielsen JN, Fredholm L, et al. Platelets and anticoagulant capacity in patients with inflammatory bowel disease. Pathophysiol Haemost Thromb 2002; 32: 92-6.
15. Turri D, Rosselli M, Simioni P, Tormone D. Factor V Leiden and prothrombotic gene mutation in inflammatory bowel disease in a Mediterranean area. Dig Liver Dis 2001; 33: 559-62.
16. Toruner M, Erkan O, Soykan I, et al. Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in inflammatory bowel disease. Turk J Gastroenterol 2004; 15: 250-2.
17. Kader HA, Berman WF, Al-Seraihy AS, Ware RE. Prevalence of factor V G1691A (Leiden), prothrombin G20210A and methylene tetrahydrofolate reductase C677T thrombophilic mutations in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 35: 629-35.
18. Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol 2000; 35: 619-23.
19. Heneghan MA, Cleary B, Murray M. Activated protein C resistance, thrombophilia, and inflammatory bowel disease. Dig Dis Sci 1998; 43: 1356-61.
20. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
21. Chiarantini E, Valanzano R, Liotta AA, et al. Hemostatic abnormalities in inflammatory bowel disease. Throm Res 1996; 82: 137-46.
22. Hudson M, Hutton RA, Wakefield AJ. Evidence for activation of coagulation in Crohn’s disease. Blood Coag Fibrinol 1992; 3: 773-8.
23. Seo M, Okada M, Tsuneyashi, et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 971-5.
24. Harvey RF, Bradshaw JM. A simple index of Crohn’s disease activity. Lancet 1980; 8: 514-5.
25. Twig G, Zandman-Goddard G, Szyper-Kravitz M, Shoenfeld Y. Systemic thromboembolism in inflammatory bowel disease: mechanism and clinical applications. Ann NY Acad Sci 2005; 1051: 166-73.
26. Over-Hamzao¤lu H, Abaci N, Ture F, et al. Prothrombotic gene mutations and Crohn’s disease, is there any association? Hepatogastroenterology 2005; 52: 1467-9.
27. Haslam N, Standen GR, Probert CS. An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999; 11: 1289-91.
28. Beauchamp NJ, Daly ME, Hampton KK, et al. High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994; 88: 219-22.
29. Rees DC. The population genetics of factor V Leiden (Arg506Gln). Br J Haemetol 1996; 95: 579-86.
30. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
31. Gurgey A, Mesci L. The prevalence of factor V Leiden (1691 G-A) mutation in Turkey. Turk J Pediatr 1997; 39: 313-5.
32. Aboud MR, Ma DDF. A comparison between two activated protein C resistance methods as routine diagnostic test for factor V Leiden mutation. Br J Haemetol 1997; 97: 798-803.
33. Bokarewa MI, Blomback M, Egberg N, Rosen S. A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coagul Fibrinolysis 1994; 5: 37-41.
34. Jackson LM, O’Gorman PJ, O’Connell J, et al. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. Q J Med 1997; 90: 183-8.
35. Helio T, Wartovaara U, Halme L. Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 170-4.
36. Papa A, De Stefano V, Gasbarrini A, Chiusolo P. Prevalence of factor V Leiden and G20210A prothrombin-gene mutation in inflammatory bowel disease. Blood Coagul Fibrinolysis 2000; 11: 499-503.
37. Over HH, Ulgen S, Tuglular T, et al. Thrombophilia and inflammatory bowel disease: does factor V mutation have a role? Eur J Gastroenterol Hepatol 1998; 10: 827-9.
38. Yılmaz U, Ayaz S, Baysal Ç, Yıldırım B. The importance of low level of free protein S in inflammatory bowel disease. Gastroenteroloji 1994; 5, 2: 300-4.
39. Stadnicki A, Bojko B, Myczkowska K. Selected risk factors of thrombotic complications in patients with ulcerative colitis. Wiad Lek. 2003; 56: 341-7.
40. Aadland E, Odegaard OR, Roseth A. Free protein S deficiency in patients with Crohn’s disease. Scand J Gastroenterol 1994; 29: 333-5.
41. Aadland E, Odegaard OR, Roseth A. Free protein S deficiency in patients in chronic inflammatory bowel disease. Scand J Gastroenterol 1992; 27: 957-60.
42. Saibeni S, Vecchi M, Valsecchi C, et al. Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance and role of antiprotein S antibodies. Dig Dis Sci 2001; 46: 637-43.
43. Lake AM, Stauffer JQ, Stuart MJ. Hemostatic alterations in inflammatory bowel disease. Response to therapy. Am J Dig Dis 1978; 23: 897-902.
44. Souto JC, Martinez E, Roca M, et al. Prothrombotic state and sign of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995; 40: 1883-9.
45. Van Bodegraven A, Schoorl M, Baak J, et al. Hemostatic imbalance in active and quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 487-92.
46. Knot E, Ten Cate JW, Leeksma OC, et al. No evidence for prethrombotic state in stable chronic inflammatory bowel disease. J Clin Pathol 1983; 36: 1387-90.
47. Stevens TRJ, James JP, Simmod NJ, et al. Circulating von Willebrand factor in inflammatory bowel disease. Gut 1992; 33: 502-6.
48. Spannagl M, Dick A, Folwaczny C, et al. Factor V Leiden mutation in patients with inflammatory bowel disease. Gastroenterology 1999; 117: 280.

APA	PAYZİN B, ADAKAN Y, YALÇIN H, ÇETİNKAYA G, BERKMEN S, ERASLAN S, Ünsal B (2006). Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease. , 183 - 190.
Chicago	PAYZİN Bahriye,ADAKAN Yeşim,YALÇIN H. Cahit,ÇETİNKAYA Gülbin S.,BERKMEN Sibel,ERASLAN Sibel,Ünsal Belkıs Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease. (2006): 183 - 190.
MLA	PAYZİN Bahriye,ADAKAN Yeşim,YALÇIN H. Cahit,ÇETİNKAYA Gülbin S.,BERKMEN Sibel,ERASLAN Sibel,Ünsal Belkıs Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease. , 2006, ss.183 - 190.
AMA	PAYZİN B,ADAKAN Y,YALÇIN H,ÇETİNKAYA G,BERKMEN S,ERASLAN S,Ünsal B Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease. . 2006; 183 - 190.
Vancouver	PAYZİN B,ADAKAN Y,YALÇIN H,ÇETİNKAYA G,BERKMEN S,ERASLAN S,Ünsal B Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease. . 2006; 183 - 190.
IEEE	PAYZİN B,ADAKAN Y,YALÇIN H,ÇETİNKAYA G,BERKMEN S,ERASLAN S,Ünsal B "Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease." , ss.183 - 190, 2006.
ISNAD	PAYZİN, Bahriye vd. "Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease". (2006), 183-190.

APA	PAYZİN B, ADAKAN Y, YALÇIN H, ÇETİNKAYA G, BERKMEN S, ERASLAN S, Ünsal B (2006). Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease. Turkish Journal of Gastroenterology, 17(3), 183 - 190.
Chicago	PAYZİN Bahriye,ADAKAN Yeşim,YALÇIN H. Cahit,ÇETİNKAYA Gülbin S.,BERKMEN Sibel,ERASLAN Sibel,Ünsal Belkıs Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease. Turkish Journal of Gastroenterology 17, no.3 (2006): 183 - 190.
MLA	PAYZİN Bahriye,ADAKAN Yeşim,YALÇIN H. Cahit,ÇETİNKAYA Gülbin S.,BERKMEN Sibel,ERASLAN Sibel,Ünsal Belkıs Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease. Turkish Journal of Gastroenterology, vol.17, no.3, 2006, ss.183 - 190.
AMA	PAYZİN B,ADAKAN Y,YALÇIN H,ÇETİNKAYA G,BERKMEN S,ERASLAN S,Ünsal B Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease. Turkish Journal of Gastroenterology. 2006; 17(3): 183 - 190.
Vancouver	PAYZİN B,ADAKAN Y,YALÇIN H,ÇETİNKAYA G,BERKMEN S,ERASLAN S,Ünsal B Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease. Turkish Journal of Gastroenterology. 2006; 17(3): 183 - 190.
IEEE	PAYZİN B,ADAKAN Y,YALÇIN H,ÇETİNKAYA G,BERKMEN S,ERASLAN S,Ünsal B "Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease." Turkish Journal of Gastroenterology, 17, ss.183 - 190, 2006.
ISNAD	PAYZİN, Bahriye vd. "Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease". Turkish Journal of Gastroenterology 17/3 (2006), 183-190.